Omega-3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birth
This clinical practice guideline on the supply of the omega-3 docosahexaenoic acid and eicosapentaenoic acid in pregnant women for risk reduction of preterm birth and early preterm birth was developed with support from several medical-scientific organizations, and is based on a review of the availab...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2023
|
| _version_ | 1824458595470671872 |
|---|---|
| author | Cetin, I Carlson, SE Burden, C da Fonseca, EB di Renzo, GC Hadjipanayis, A Harris, WS Kumar, KR Olsen, SF Mader, MS McAuliffe, FM Muhlhausler, B Oken, E Poon, LC Poston, L Ramakrishnan, U Roehr, CC Savona-Ventura, C Smuts, CM Sotiriadis, A Su, K-P Tribe, RM Vannice, G Koletzko, B Clinical Practice Guideline |
| author2 | Asia Pacific Health Association (Pediatric-Neonatology Branch) |
| author_facet | Asia Pacific Health Association (Pediatric-Neonatology Branch) Cetin, I Carlson, SE Burden, C da Fonseca, EB di Renzo, GC Hadjipanayis, A Harris, WS Kumar, KR Olsen, SF Mader, MS McAuliffe, FM Muhlhausler, B Oken, E Poon, LC Poston, L Ramakrishnan, U Roehr, CC Savona-Ventura, C Smuts, CM Sotiriadis, A Su, K-P Tribe, RM Vannice, G Koletzko, B Clinical Practice Guideline |
| author_sort | Cetin, I |
| collection | OXFORD |
| description | This clinical practice guideline on the supply of the omega-3 docosahexaenoic acid and eicosapentaenoic acid in pregnant women for risk reduction of preterm birth and early preterm birth was developed with support from several medical-scientific organizations, and is based on a review of the available strong evidence from randomized clinical trials and a formal consensus process. We concluded the following. Women of childbearing age should obtain a supply of at least 250 mg/d of docosahexaenoic+eicosapentaenoic acid from diet or supplements, and in pregnancy an additional intake of ≥100 to 200 mg/d of docosahexaenoic acid. Pregnant women with a low docosahexaenoic acid intake and/or low docosahexaenoic acid blood levels have an increased risk of preterm birth and early preterm birth. Thus, they should receive a supply of approximately 600 to 1000 mg/d of docosahexaenoic+eicosapentaenoic acid, or docosahexaenoic acid alone, given that this dosage showed significant reduction of preterm birth and early preterm birth in randomized controlled trials. This additional supply should preferably begin in the second trimester of pregnancy (not later than approximately 20 weeks’ gestation) and continue until approximately 37 weeks’ gestation or until childbirth if before 37 weeks’ gestation. Identification of women with inadequate omega-3 supply is achievable by a set of standardized questions on intake. Docosahexaenoic acid measurement from blood is another option to identify women with low status, but further standardization of laboratory methods and appropriate cutoff values is needed. Information on how to achieve an appropriate intake of docosahexaenoic acid or docosahexaenoic+eicosapentaenoic acid for women of childbearing age and pregnant women should be provided to women and their partners. |
| first_indexed | 2024-03-07T08:18:46Z |
| format | Journal article |
| id | oxford-uuid:7627589c-6776-49ea-bc64-2d32cc15aabc |
| institution | University of Oxford |
| language | English |
| last_indexed | 2025-02-19T04:28:23Z |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:7627589c-6776-49ea-bc64-2d32cc15aabc2024-12-09T09:59:39ZOmega-3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birthJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7627589c-6776-49ea-bc64-2d32cc15aabcEnglishSymplectic ElementsElsevier2023Cetin, ICarlson, SEBurden, Cda Fonseca, EBdi Renzo, GCHadjipanayis, AHarris, WSKumar, KROlsen, SFMader, MSMcAuliffe, FMMuhlhausler, BOken, EPoon, LCPoston, LRamakrishnan, URoehr, CCSavona-Ventura, CSmuts, CMSotiriadis, ASu, K-PTribe, RMVannice, GKoletzko, BClinical Practice GuidelineAsia Pacific Health Association (Pediatric-Neonatology Branch)Child Health Foundation (Stiftung Kindergesundheit)European Academy of PaediatricsEuropean Board & College of Obstetrics and GynaecologyEuropean Foundation for the Care of Newborn InfantsEuropean Society for Paediatric ResearchInternational Society for Developmental Origins of Health and DiseaseThis clinical practice guideline on the supply of the omega-3 docosahexaenoic acid and eicosapentaenoic acid in pregnant women for risk reduction of preterm birth and early preterm birth was developed with support from several medical-scientific organizations, and is based on a review of the available strong evidence from randomized clinical trials and a formal consensus process. We concluded the following. Women of childbearing age should obtain a supply of at least 250 mg/d of docosahexaenoic+eicosapentaenoic acid from diet or supplements, and in pregnancy an additional intake of ≥100 to 200 mg/d of docosahexaenoic acid. Pregnant women with a low docosahexaenoic acid intake and/or low docosahexaenoic acid blood levels have an increased risk of preterm birth and early preterm birth. Thus, they should receive a supply of approximately 600 to 1000 mg/d of docosahexaenoic+eicosapentaenoic acid, or docosahexaenoic acid alone, given that this dosage showed significant reduction of preterm birth and early preterm birth in randomized controlled trials. This additional supply should preferably begin in the second trimester of pregnancy (not later than approximately 20 weeks’ gestation) and continue until approximately 37 weeks’ gestation or until childbirth if before 37 weeks’ gestation. Identification of women with inadequate omega-3 supply is achievable by a set of standardized questions on intake. Docosahexaenoic acid measurement from blood is another option to identify women with low status, but further standardization of laboratory methods and appropriate cutoff values is needed. Information on how to achieve an appropriate intake of docosahexaenoic acid or docosahexaenoic+eicosapentaenoic acid for women of childbearing age and pregnant women should be provided to women and their partners. |
| spellingShingle | Cetin, I Carlson, SE Burden, C da Fonseca, EB di Renzo, GC Hadjipanayis, A Harris, WS Kumar, KR Olsen, SF Mader, MS McAuliffe, FM Muhlhausler, B Oken, E Poon, LC Poston, L Ramakrishnan, U Roehr, CC Savona-Ventura, C Smuts, CM Sotiriadis, A Su, K-P Tribe, RM Vannice, G Koletzko, B Clinical Practice Guideline Omega-3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birth |
| title | Omega-3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birth |
| title_full | Omega-3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birth |
| title_fullStr | Omega-3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birth |
| title_full_unstemmed | Omega-3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birth |
| title_short | Omega-3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birth |
| title_sort | omega 3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birth |
| work_keys_str_mv | AT cetini omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT carlsonse omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT burdenc omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT dafonsecaeb omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT direnzogc omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT hadjipanayisa omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT harrisws omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT kumarkr omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT olsensf omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT maderms omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT mcauliffefm omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT muhlhauslerb omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT okene omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT poonlc omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT postonl omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT ramakrishnanu omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT roehrcc omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT savonaventurac omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT smutscm omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT sotiriadisa omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT sukp omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT triberm omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT vanniceg omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT koletzkob omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth AT clinicalpracticeguideline omega3fattyacidsupplyinpregnancyforriskreductionofpretermandearlypretermbirth |